Cat. No.: DIA-0231221
Product Information | |
---|---|
CAS No. | 319460-85-0 |
Synonyms | AG 013736 |
Formula | C22H18N4OS |
Molecular Weight | 386.47 |
SMILES | CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=N[NH]3)\C=C\C4=CC=CC=N4 |
Target | VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit |
Product Description | Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively. |
Format & Storage | |
---|---|
Purity | > 99% |
Shipping | Shipped on dry ice. |
Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.